MarioDavidSaltarelliMDPHD

PubMed

• 17 citations
  Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.
  Robert A. Lenz, Yili Pritchett, Scott M. Berry, Daniel A. Llano, Shu Han, Donald A. Berry, Carl H. Sadowsky, Walid M. Abi-Saab, Mario D. Saltarelli> ;Alzheimer Disease and Associated Disorders. 2015 Sep 7
• 40 citations
  A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD
  Earle E. Bain, Weining Z. Robieson, Yili Pritchett, Tushar S. Garimella, Walid Abi-Saab, George Apostol, James J. McGough, Mario D. Saltarelli> ;Neuropsychopharmacology. 2013 Feb 1
• 13 citations
  A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
  Earle E. Bain, George Apostol, R. Bart Sangal, Weining Z. Robieson, Dawnelle L. McNeill, Walid M. Abi-Saab, Mario D. Saltarelli> ;The Journal of Clinical Psychiatry. 2012 Jun 15
• 45 citations
  The scopolamine model as a pharmacodynamic marker in early drug development
  Robert A. Lenz, Jeffrey D. Baker, Charles Locke, Lynne E. Rueter, Eric G. Mohler, Keith Wesnes, Walid M. Abi-Saab, Mario D. Saltarelli> ;Psychopharmacology. 2012 Mar 1
• 41 citations
  Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double...
  George Apostol, Walid M. Abi-Saab, Christopher J. Kratochvil, Lenard A. Adler, Weining Z. Robieson, Laura M. Gault, Yili Pritchett, David Feifel, Michelle A. Collins, ...> ;Psychopharmacology. 2012 Feb 1
• 28 citations
  A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia
  Laura Redden, Beatrice Rendenbach-Mueller, Walid M. Abi-Saab, David A. Katz, Armen Goenjian, Weining Z. Robieson, Yaqin Wang, Sandra L. Goss, Nicholas Greco, Mario Dav...> ;Journal of Clinical Psychopharmacology. 2011 Apr 1
• 35 citations
  Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
  Laura Redden, Yili Pritchett, Weining Z. Robieson, Xenia Kovacs, Mary Garofalo, Katherine Tracy, Mario David Saltarelli> ;Annals of General Psychiatry. 2011 Jan 18
• 30 citations
  Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: Results from two randomized placebo-controlled clinical trials
  Timothy E. Wilens, Laura M. Gault, Ann C. Childress, Christopher J. Kratochvil, Lindsey Bensman, Coleen Hall, Evelyn Olson, Weining Z. Robieson, Tushar Garimella, Wali...> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2011 Jan 1
• 4 citations
  D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET - a response
  Mark L. Day, Earle E. Bain, Gerard J. Marek, Mario David Saltarelli, Gerard B. Fox> ;The International Journal of Neuropsychopharmacology. 2010 Apr 1
• 60 citations
  Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
  Ariel Graff-Guerrero, Laura Redden, Walid M. Abi-Saab, David A. Katz, Sylvain Houle, Penny Barsoum, Anahita Bhathena, Ramesh Palaparthy, Mario David Saltarelli, Shitij...> ;The International Journal of Neuropsychopharmacology. 2010 Apr 1
• 2 citations
  Divalproex sodium in children with partial seizures: 12-month safety study.
  Robert A. Lenz, Roy D. Elterman, Weining Z. Robieson, Namita V. Vigna, Mario D. Saltarelli> ;Pediatric Neurology. 2009 Aug 1
• 9 citations
  Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers.
  Evan D. Kharasch, Gowdahalli N. Subbarao, Keith R. Cromack, Dennis A. Stephens, Mario D. Saltarelli> ;Anesthesia and Analgesia. 2009 Jun 1
• 70 citations
  A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents
  Karen Dineen Wagner, Laura Redden, Robert A. Kowatch, Timothy E. Wilens, Scott Segal, Kiki D. Chang, Patricia Wozniak, Namita V. Vigna, Walid M. Abi-Saab, Mario D. Sal...> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2009 May 1
• 39 citations
  Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia
  Daniel E. Casey, David G. Daniel, Carol A. Tamminga, John M. Kane, Tram Tran-Johnson, Patricia Wozniak, Walid M. Abi-Saab, Jeff Baker, Laura Redden, Nicholas Greco, Ma...> ;Neuropsychopharmacology. 2009 Apr 1
• 22 citations
  Long-Term Safety of Divalproex Sodium Extended-Release in Children and Adolescents with Bipolar I Disorder
  Laura Redden, Melissa P. DelBello, Karen Dineen Wagner, Timothy E. Wilens, Shishuka Malhotra, Patricia Wozniak, Namita V. Vigna, Nicholas Greco, Xenia Kovacs, Walid M....> ;Journal of Child and Adolescent Psychopharmacology. 2009 Feb 22
• 15 citations
  Safety and Tolerability of Divalproex Sodium Extended‐Release in the Prophylaxis of Migraine Headaches: Results of an Open‐Label Extension Trial in Adolescents
  George Apostol, Ann Pakalnis, Genevieve A. Laforet, Weining Z. Robieson, Evelyn Olson, Walid M. Abi-Saab, Mario D. Saltarelli> ;Headache. 2009 Jan 1
• 23 citations
  Divalproex Sodium Extended‐Release for the Prophylaxis of Migraine Headache in Adolescents: Results of a Stand‐Alone, Long‐Term Open‐Label Safety Study
  George Apostol, Donald W. Lewis, Genevieve A. Laforet, Weining Z. Robieson, Julie M. Fugate, Walid M. Abi-Saab, Mario D. Saltarelli> ;Headache. 2009 Jan 1
• 37 citations
  Divalproex Extended-Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double-Blind, Placebo-Controlled Study
  George Apostol, Roger Cady, Genevieve A. Laforet, Weining Z. Robieson, Evelyn Olson, Walid M. Abi-Saab, Mario D. Saltarelli> ;Headache. 2008 Jul 1
• 83 citations
  A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania
  Charles L. Bowden, Alan C. Swann, Joseph R. Calabrese, Leon M. Rubenfaer, Patricia Wozniak, Michelle A. Collins, Walid M. Abi-Saab, Mario D. Saltarelli> ;The Journal of Clinical Psychiatry. 2006 Oct 16
• 54 citations
  Expression of the rat brain creatine transporter in situ and in transfected HeLa cells.
  Mario D. Saltarelli, Andrea L. Bauman, Kimberly R. Moore, Christopher C. Bradley, Randy D. Blakely> ;Developmental Neuroscience. 1996 Jan 1
• 5 citations
  [3H]hemicholinium-3 binding in rats with status epilepticus induced by lithium chloride and pilocarpine.
  Kiyofumi Yamada, Mario D. Saltarelli, Joseph T. Coyle> ;European Journal of Pharmacology. 1991 Apr 3
• 7 citations
  Effects of calmodulin antagonists on sodium-dependent high-affinity choline uptake.
  Kiyofumi Yamada, Mario D. Saltarelli, Joseph T. Coyle> ;Brain Research. 1991 Feb 22
• Phospholipase A2 and 3H-hemicholinium-3 binding sites in rat brain: a potential second-messenger role for fatty acids in the regulation of high-affinity choline uptake.
  Saltarelli MD, Yamada K, Coyle JT> ;J. Neurosci.. 1990-01-01
• 20 citations
  The role of calcium in the regulation of [3H]hemicholinium-3 binding sites in rat brain.
  Mario D. Saltarelli, J. Lopez, Pedro R. Lowenstein, Joseph T. Coyle> ;Neuropharmacology. 1988 Dec 1
• 20 citations
  Involvement of phospholipase A2 in the regulation of [3H]hemicholinium-3 binding
  Kiyofumi Yamada, Mario D. Saltarelli, Joseph T. Coyle> ;Biochemical Pharmacology. 1988 Nov 15
• Join now to see all